JP2019501132A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501132A5 JP2019501132A5 JP2018526675A JP2018526675A JP2019501132A5 JP 2019501132 A5 JP2019501132 A5 JP 2019501132A5 JP 2018526675 A JP2018526675 A JP 2018526675A JP 2018526675 A JP2018526675 A JP 2018526675A JP 2019501132 A5 JP2019501132 A5 JP 2019501132A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- fab fragment
- antibody fab
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259227P | 2015-11-24 | 2015-11-24 | |
| US62/259,227 | 2015-11-24 | ||
| PCT/US2016/063587 WO2017091719A1 (en) | 2015-11-24 | 2016-11-23 | Anti-complement factor c1q fab fragments and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501132A JP2019501132A (ja) | 2019-01-17 |
| JP2019501132A5 true JP2019501132A5 (https=) | 2020-01-09 |
| JP6976943B2 JP6976943B2 (ja) | 2021-12-08 |
Family
ID=58763681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526675A Active JP6976943B2 (ja) | 2015-11-24 | 2016-11-23 | 抗補体因子Ｃ１ｑ Ｆａｂ断片及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10723788B2 (https=) |
| EP (1) | EP3380518B1 (https=) |
| JP (1) | JP6976943B2 (https=) |
| KR (1) | KR102877741B1 (https=) |
| CN (2) | CN108779171B (https=) |
| AU (1) | AU2016361517C1 (https=) |
| IL (2) | IL296130A (https=) |
| SG (1) | SG11201803703UA (https=) |
| WO (1) | WO2017091719A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3597747B1 (en) | 2012-08-24 | 2023-03-15 | Chugai Seiyaku Kabushiki Kaisha | Mouse fcgammarii-specific fc antibody |
| AU2014250434B2 (en) | 2013-04-02 | 2019-08-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
| WO2015006507A1 (en) | 2013-07-09 | 2015-01-15 | Annexon, Inc. | Methods of treatment for alzheimer's disease and huntington's disease |
| HUE070383T2 (hu) | 2014-11-05 | 2025-06-28 | Annexon Inc | Humanizált C1Q anti-komplement faktor antitestek és alkalmazásaik |
| WO2017091719A1 (en) | 2015-11-24 | 2017-06-01 | Annexon, Inc. | Anti-complement factor c1q fab fragments and uses thereof |
| EP3710589A4 (en) | 2017-11-14 | 2021-11-10 | Chugai Seiyaku Kabushiki Kaisha | ANTI-C1S ANTIBODIES AND METHOD OF USING |
| CR20200542A (es) * | 2018-04-13 | 2021-01-18 | Chugaiseiyaku Kk | Anticuerpos anti-componente de complemento y métodos de uso |
| WO2020121282A1 (en) | 2018-12-13 | 2020-06-18 | Argenx Bvba | Antibodies to human complement factor c2b and methods of use |
| MX2021013441A (es) | 2019-05-15 | 2021-12-10 | Chugai Pharmaceutical Co Ltd | Molecula de union a antigenos, composicion farmaceutica y metodo. |
| GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
| WO2021076991A1 (en) * | 2019-10-17 | 2021-04-22 | Annexon, Inc. | Compositions and methods for treating blood disorders |
| CN110716038B (zh) * | 2019-10-23 | 2022-08-30 | 俞梦越 | 一种急性冠脉综合征补体检测试剂盒及其使用方法 |
| US20240034775A1 (en) * | 2020-05-05 | 2024-02-01 | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads | Compositions and methods for treating epilepsy |
| CN112194719A (zh) * | 2020-09-01 | 2021-01-08 | 中日友好医院(中日友好临床医学研究所) | Crt抗原和mage-a1抗原的制备及其应用 |
| CN112837822B (zh) * | 2020-09-24 | 2023-05-02 | 广州市疾病预防控制中心(广州市卫生检验中心、广州市食品安全风险监测与评估中心、广州医科大学公共卫生研究院) | 预测covid-19患者发生轻至重度进展的标志物及试剂盒和建立方法 |
| CA3195798A1 (en) * | 2020-10-16 | 2022-04-21 | Ted Yednock | Compositions and methods for treating blood disorders |
| WO2022120137A1 (en) * | 2020-12-04 | 2022-06-09 | Annexon, Inc. | Compositions and methods for treating ocular diseases |
| WO2023114763A1 (en) * | 2021-12-13 | 2023-06-22 | Annexon, Inc. | Anti-complement factor c1q antibodies with single binding arms and uses thereof |
| JP2025503545A (ja) * | 2021-12-30 | 2025-02-04 | アネクソン，インコーポレーテッド | ハンチントン病を治療するための組成物及び方法 |
| KR20250006238A (ko) * | 2022-04-29 | 2025-01-10 | 애넥슨, 인코포레이티드 | 안구 질환을 치료하기 위한 조성물 및 방법 |
| CN119677537A (zh) * | 2022-05-13 | 2025-03-21 | 安尼艾克松股份有限公司 | 用于治疗狼疮性肾炎的组合物和方法 |
| CN119371528B (zh) * | 2024-10-30 | 2025-06-24 | 泰州市人民医院 | 一种C1q抗体及其应用、一种抑制补体经典途径活化的药剂及其应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4595654A (en) | 1983-11-07 | 1986-06-17 | Immunomedics Inc. | Method for detecting immune complexes in serum |
| US6717031B2 (en) | 1995-06-07 | 2004-04-06 | Kate Dora Games | Method for selecting a transgenic mouse model of alzheimer's disease |
| US20020058311A1 (en) | 1995-06-13 | 2002-05-16 | Browne Michael Jospeh | Chimeric leptin fused to immunoglobulin domain and use |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| WO1998023761A1 (en) | 1996-11-27 | 1998-06-04 | Genentech, Inc. | HUMANIZED ANTI-CD11a ANTIBODIES |
| US20050197285A1 (en) | 1997-03-07 | 2005-09-08 | Rosen Craig A. | Human secreted proteins |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| WO1999010492A1 (en) | 1997-08-26 | 1999-03-04 | Zymogenetics, Inc. | Adipocyte-specific protein homologs |
| US20030170781A1 (en) | 1999-07-01 | 2003-09-11 | Zymogenetics, Inc. | Secreted protein zacrp4 |
| WO2002005634A2 (en) | 2000-07-13 | 2002-01-24 | University Of South Florida | Transgenic animal and methods |
| AU2002226074A1 (en) | 2000-10-26 | 2002-05-06 | Wisconsin Alumni Research Foundation. | E. coli 0157:h7 c1 esterase inhibitor-binding protein stce and uses thereof |
| US7189830B2 (en) | 2001-02-19 | 2007-03-13 | Merck Patent Gmbh | Anti-KSA/IL-2 fusion proteins with reduced immunogenicity |
| CA2478313A1 (en) | 2001-11-07 | 2003-06-26 | Human Genome Sciences, Inc. | 41 human secreted proteins |
| US20040248156A1 (en) | 2001-12-03 | 2004-12-09 | Tianhua Hu | Methods and materials relating to novel C1q domain-containing polypeptides and polynucleotides |
| US20050214786A1 (en) | 2002-02-22 | 2005-09-29 | Human Genome Sciences, Inc. | 26 human secreted proteins |
| US8329169B2 (en) | 2003-05-15 | 2012-12-11 | Genentech, Inc. | Methods and compositions for the prevention and treatment of sepsis |
| US20050019326A1 (en) | 2003-06-16 | 2005-01-27 | The Brigham And Women's Hospital, Inc. | C1q complement inhibitors and methods of use thereof |
| WO2005002512A2 (en) | 2003-06-19 | 2005-01-13 | University Of Rochester | Immunotherapeutic vaccine strategy |
| US8501705B2 (en) | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| KR100956913B1 (ko) | 2003-12-19 | 2010-05-11 | 제넨테크, 인크. | 치료제로서 유용한 일가 항체 단편 |
| CN101001872A (zh) * | 2004-04-16 | 2007-07-18 | 宏观基因有限公司 | FcγRIIB－特异性抗体及其使用方法 |
| US7544855B2 (en) | 2004-04-23 | 2009-06-09 | Buck Institute | Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664 |
| US20080008719A1 (en) | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
| WO2006063150A2 (en) | 2004-12-08 | 2006-06-15 | Immunomedics, Inc. | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer |
| TWI319708B (en) | 2005-10-14 | 2010-01-21 | Methods and compositions for altering cell fuction | |
| US9480658B2 (en) | 2005-12-09 | 2016-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of synaptic maintenance |
| US8148330B2 (en) | 2005-12-09 | 2012-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of synaptic maintenance |
| RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| US7919079B2 (en) * | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
| CA2662480C (en) | 2006-09-05 | 2016-11-08 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
| CN101657097A (zh) | 2007-03-01 | 2010-02-24 | 先进视觉疗法公司 | 以炎症为特征的疾病的治疗 |
| UY31520A1 (es) | 2007-12-11 | 2009-08-03 | Proteinas de union a antigenos | |
| CR20170001A (es) * | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
| WO2010065425A1 (en) | 2008-12-01 | 2010-06-10 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for detection of complement fixing antibodies |
| WO2010125763A1 (ja) | 2009-04-28 | 2010-11-04 | パナソニック株式会社 | 受信装置 |
| WO2012067267A1 (en) | 2010-11-18 | 2012-05-24 | Takahiro Ochi | TESTING METHOD USING ANTI-C1q MONOCLONAL ANTIBODY |
| CA2833820C (en) | 2011-05-27 | 2019-10-29 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) -binding proteins |
| WO2012176765A1 (ja) | 2011-06-24 | 2012-12-27 | 株式会社ペルセウスプロテオミクス | 抗ヒトｐ－カドへリン（ｃｄｈ３）遺伝子組み換え抗体 |
| LT2794905T (lt) | 2011-12-20 | 2020-07-10 | Medimmune, Llc | Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams |
| US20150125449A1 (en) | 2012-05-10 | 2015-05-07 | Zymeworks Inc. | Single-Arm Monovalent Antibody Constructs and Uses Thereof |
| KR102339315B1 (ko) | 2012-06-18 | 2021-12-15 | 오메로스 코포레이션 | 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법 |
| CN104870475B (zh) | 2012-10-25 | 2019-11-08 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
| DK2914291T3 (da) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| WO2014161570A1 (en) | 2013-04-03 | 2014-10-09 | Roche Glycart Ag | Antibodies against human il17 and uses thereof |
| EP2983710B1 (en) | 2013-04-09 | 2019-07-31 | Annexon, Inc. | Methods of treatment for neuromyelitis optica |
| EP2996722A4 (en) | 2013-05-15 | 2017-01-11 | Annexon, Inc. | Methods of treatment for guillain-barre syndrome |
| WO2015006507A1 (en) | 2013-07-09 | 2015-01-15 | Annexon, Inc. | Methods of treatment for alzheimer's disease and huntington's disease |
| HUE070383T2 (hu) * | 2014-11-05 | 2025-06-28 | Annexon Inc | Humanizált C1Q anti-komplement faktor antitestek és alkalmazásaik |
| WO2017091719A1 (en) | 2015-11-24 | 2017-06-01 | Annexon, Inc. | Anti-complement factor c1q fab fragments and uses thereof |
| KR20190005944A (ko) * | 2016-05-09 | 2019-01-16 | 애넥슨, 인코포레이티드 | 척수성 근위축 치료용 조성물 및 방법 |
| CA3030872A1 (en) * | 2016-07-19 | 2018-01-25 | Annexon, Inc. | Compositions and methods for treating frontotemporal dementia |
| WO2022034920A1 (en) | 2020-08-14 | 2022-02-17 | Chugai Seiyaku Kabushiki Kaisha | One-armed antigen-binding molecules and uses thereof |
| WO2022120137A1 (en) | 2020-12-04 | 2022-06-09 | Annexon, Inc. | Compositions and methods for treating ocular diseases |
-
2016
- 2016-11-23 WO PCT/US2016/063587 patent/WO2017091719A1/en not_active Ceased
- 2016-11-23 KR KR1020187017912A patent/KR102877741B1/ko active Active
- 2016-11-23 JP JP2018526675A patent/JP6976943B2/ja active Active
- 2016-11-23 CN CN201680079670.4A patent/CN108779171B/zh active Active
- 2016-11-23 SG SG11201803703UA patent/SG11201803703UA/en unknown
- 2016-11-23 EP EP16869264.8A patent/EP3380518B1/en active Active
- 2016-11-23 US US15/360,549 patent/US10723788B2/en active Active
- 2016-11-23 AU AU2016361517A patent/AU2016361517C1/en active Active
- 2016-11-23 CN CN202210711282.0A patent/CN115260310B/zh active Active
- 2016-11-23 IL IL296130A patent/IL296130A/en unknown
-
2018
- 2018-05-01 IL IL259079A patent/IL259079B2/en unknown
-
2020
- 2020-06-25 US US16/911,954 patent/US11999779B2/en active Active
-
2024
- 2024-05-31 US US18/680,437 patent/US20250002567A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501132A5 (https=) | ||
| JP2018501813A5 (https=) | ||
| JP2016526393A5 (https=) | ||
| JP7627045B2 (ja) | 新規抗－ｃ－ｋｉｔ抗体 | |
| US20250002567A1 (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| US9856321B2 (en) | Anti-DR5 antibodies, polynucleotides and methods | |
| JP2019518459A (ja) | Ｌａｇ−３抗体、その抗原結合フラグメント、およびそれらの医薬的用途 | |
| FI3019240T3 (fi) | Anti-komplementtitekijä c1q -vasta-aineita ja niiden käyttöjä | |
| JP2011504872A5 (https=) | ||
| JPWO2020014617A5 (https=) | ||
| US12486322B2 (en) | Anti-complement factor C1q antibodies with single binding arms and uses thereof | |
| EP3990488A1 (en) | Semaphorin 3a antibodies and uses thereof | |
| CN113621066A (zh) | 一种抗pd-1抗体及其晶体制备方法 | |
| US20240376186A1 (en) | C3b-Binding Fusion Proteins | |
| NZ732156B2 (en) | Humanized anti-complement factor c1q antibodies and uses thereof | |
| NZ742877B2 (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| NZ732156A (en) | Humanized anti-complement factor c1q antibodies and uses thereof | |
| HK40083120A (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| NZ769628B2 (en) | Humanized anti-complement factor C1q antibodies and uses thereof | |
| CA3006092C (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| CN119907685A (zh) | 用于抗c1q抗体的制剂 | |
| HK1262078A1 (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| HK1262078B (en) | Anti-complement factor c1q fab fragments and uses thereof |